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Abstract
Chronic treatment with b2 adrenoceptor agonists is recommended as a first-line
maintenance therapy for chronic obstructive pulmonary disease (COPD). How-
ever, a potential consequence of long-term treatment may be the loss of func-
tional response (tachyphylaxis) over time. In this study, we have investigated
the tendency of such agonists, with a range of efficacies, to develop functional
desensitization to cAMP responses in primary human bronchial smooth muscle
cells following prolonged agonist exposure. The data show that upon repeat
exposure, all agonists produced functional desensitization to the same degree
and rate. In addition, b2 adrenoceptor internalization and b-arrestin-2 recruit-
ment were monitored using b2eGFP visualization and the PathHunterTM b-
arrestin-2 assay, respectively. All agonists were capable of causing robust recep-
tor internalization and b-arrestin-2 recruitment, the rate of which was
influenced by agonist efficacy, as measured in those assays. In summary,
although a relationship exists between agonist efficacy and the rate of both
receptor internalization and b-arrestin-2 recruitment, there is no correlation
between agonist efficacy and the rate or extent of functional desensitization.
Abbreviations
ANOVA, analysis of variance; BSA, bovine serum albumin; COPD, chronic obstruc-
tive pulmonary disease; FBS, fetal bovine serum; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; GPCR, G protein coupled receptor; hBSMc,
human bronchial smooth muscle cells; HBSS, Hank’s balanced salt solution; ICC,
immunocytochemical; IFC, immunofluorescent; LABA, long-acting b2 adrenoceptor
agonists; SABA, short-acting b2 adrenoceptor agonists.
Introduction
Inhaled b2 adrenoceptor agonists are widely used for the
treatment of asthma and chronic obstructive pulmonary
disease (COPD), providing symptomatic relief by induc-
ing bronchodilation via relaxation of airway smooth mus-
cle. Specifically, relaxation is brought about when these
agonists activate b2 adrenoceptors expressed on airway
smooth muscle cells, increasing the activity of adenylate
cyclase and leading to increases in intracellular levels of
cAMP. The b2 adrenoceptor agonists currently used in
the management of asthma and COPD can be classified
as either short-acting b2 adrenoceptor agonists (SABA),
for example, salbutamol; long-acting b2 adrenoceptor
agonists (LABA), for example, formoterol and salmeterol;
or ultra LABA, for example, indacaterol, which is based
on their duration of action after a single inhaled dose,
that is, 4–6, 12, and 24 h, respectively. Short-acting agon-
ists are recommended as first-line monotherapy for
patients with mild COPD, whereas for patients with more
a more severe disease state, longer acting b2 adrenoceptor
agonists are recommended, either for use alone or in
combination with inhaled corticosteroids (Global Strategy
for the Diagnosis, Management and Prevention of COPD,
Global Initiative for Chronic Obstructive Lung Disease
[GOLD] 2013).
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Chronic treatment with b2 adrenoceptor agonists are
recommended as a first-line maintenance therapy for
COPD. However, a potential consequence of long-term
treatment may be the loss of functional response (tachy-
phylaxis) over time through G protein coupled receptor
(GPCR) desensitization. There have been a number of
studies exploring loss of clinical responsiveness to LABA
therapy in the clinic within the first 2 weeks of beginning
treatment (Bhagat et al. 1995; Aziz et al. 1998; Drotar
et al. 1998; Giannini et al. 2011). This loss of responsive-
ness usually manifests itself as a rapid desensitization to
the bronchoprotection afforded by LABA therapy, possi-
bly through tachyphylaxis of receptor signaling on inflam-
matory cells, in particular mast cells (Scola et al. 2004,
2009). However, the bronchodilator properties of LABA
therapy appear to be much more resistant to tolerance,
possibly due to the higher receptor reserve present in air-
way smooth muscle cells, compared to mast cells (Chong
and Peachell 1999; Giembycz 2009), or the relatively
lower expression of proteins involved in receptor regula-
tion (McGraw and Liggett 1997). The amount of tachy-
phylaxis to chronic LABA therapy has been less
comprehensively studied, and many of the results are
contradictory and often complicated by differences in
study design. In some cases salmeterol has been shown to
produce tolerance to bronchodilation (Donohue et al.
2002, 2003) compared to long-acting muscarinic antago-
nist therapy. In other studies there was no evidence of
tolerance to chronic treatment of either formoterol or
salmeterol (FitzGerald et al. 1999; Hanania et al. 2005).
In a more recent study, salmeterol and formoterol were
shown to suffer from a slight loss of efficacy between 13
and 52 weeks of continuous treatment although it was
not found to be significant in terms of clinically meaning-
ful outcomes (Donohue et al. 2008).
The suggestion that chronic treatment with higher effi-
cacy agonists may lead to more tachyphylaxis is a much
debated topic. Developing a better understanding of the
relationship between agonist efficacy and the functional
desensitization of receptors may aid in the interpretation
of observed clinical responses to agonist-based therapies,
including b2 adrenoceptor agonists, and importantly, may
also help illuminate best therapeutic approaches for future
treatment paradigms with agonist-based therapies. Early
studies examining the desensitization of the b2 adreno-
ceptor showed a clear relationship between agonist effi-
cacy and receptor desensitization, with partial b2 agonists
causing less phosphorylation and internalization than full
agonists (January et al. 1997; Clark et al. 1999; Moore
et al. 2007). However, these early experiments conducted
with the b2 agonists were designed so that receptor occu-
pancy was matched for each agonist, regardless of efficacy.
This effectively negated any influence of receptor reserve
(spare receptors not required to produce a maximum
response in the presence of the agonist). In the clinic, the
dose of agonist chosen to treat patients is determined
based on therapeutic effect (e.g., bronchodilation) and
not on receptor occupancy. A more recent study by
D€uringer et al. (2009) addressed this problem by compar-
ing the desensitization profile of b2 agonists at equi-effec-
tive concentrations (i.e., concentrations that produce
equal functional responses), rather than equal occupancy,
thus more closely reflecting the clinical situation. This
study showed that under conditions of continuous ago-
nist stimulation, reduction in receptor responsiveness was
proportional to the initial functional effect and similar for
all agonists studied. These results were in contrast to pre-
vious studies, questioning whether high-efficacy agonists
necessarily induce more desensitization than partial agon-
ists (Charlton 2009).
In the clinic, an acute (sudden) loss in response to a
drug after its administration is termed tachyphylaxis.
When the same effect is observed in vitro in experiments
using cell cultures or isolated tissues we use the term
desensitization. However, the term desensitization is also
used to describe many of the individual processes in the
pathway leading to desensitization such as b-arrestin-2
recruitment, receptor phosphorylation, and internaliza-
tion, and recent studies suggest that these processes do
not necessarily shut down receptor-mediated signaling.
Indeed, it has been shown that some internalized recep-
tors, including the b2 adrenoceptor, are still capable of
signaling from endosomes (Mullershausen et al. 2009;
Calebiro et al. 2010; Irannejad et al. 2013) and that b-
arrestin-2 is a signaling molecule in its own right, able to
initiate non-G protein-mediated pathways upon recruit-
ment to the receptor (Wei et al. 2003; Shenoy and Lefko-
witz 2005). It is therefore important to clarify the
terminology used in this manuscript. The IUPHAR guide
on terms used in Quantitative Pharmacology states that
tachyphylaxis and desensitization are “overlapping terms
that refer to a spontaneous decline in the response to a
continuous application of agonist, or to repeated applica-
tions or doses. No mechanism is implied by either term,
and it is recommended that desensitization be used when
the fade or tachyphylaxis is considered to be a direct
consequence of receptor activation” (Neubig et al. 2003).
As we feel that tachyphylaxis is a term more commonly
used to describe this loss of response in in vivo or clini-
cal settings, we have chosen desensitization as a more
appropriate term for these in vitro studies and further
clarified the term as “functional desensitization” to
describe a loss in functional cAMP response following
agonist administration. This term is intended to encom-
pass a number of mechanisms including G protein
uncoupling, receptor phosphorylation, b-arrestin recruit-
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ment, receptor internalization, and downregulation, all of
which may contribute to an overall loss in the ability of
the cells to respond to agonists and produce cAMP. This
we believe to be the most appropriate readout of tachy-
phylaxis. In addition, we have used the term receptor
modifications to incorporate biochemical processes such
as b-arrestin-2 recruitment, receptor phosphorylation,
and internalization.
The present study was conducted to compare the abil-
ity of a number of b2 adrenoceptor agonists with a range
of intrinsic efficacies to cause functional desensitization in
primary human bronchial smooth muscle cells. In an
attempt to more accurately reflect the conditions in the
clinic, whereby patients are on continuous treatment with
the same LABA to maintain target coverage, we have used
the same agonist for the subsequent rechallenge after
prolonged agonist treatment. In addition, we have studied
b-arrestin-2 recruitment and receptor internalization in
two highly sensitive recombinant systems. Our results
show all of the agonists tested were able to recruit b-arr-
estin-2 and promote receptor internalization with a range
of intrinsic efficacies. When cAMP accumulation was
studied following prolonged exposure to each agonist it
was shown that all of the agonists produced the same
degree of functional desensitization. We therefore conclude
that there is no correlation between intrinsic efficacy for
cAMP accumulation and functional desensitization of this
response.
Materials and Methods
Materials
PathHunterTM CHO-K1 b2-adrencoceptor: b-arrestin-2
cells (CHO-b2:arrestin) and PathHunter
TM lysis and Flash
detection reagents were purchased from DiscoveRx (Bir-
mingham, UK). Human bronchial smooth muscle cells
were purchased from Lonza (Slough, UK). McCoys 5A,
Ham’s F12 media supplemented with L-glutamine, CO2-
independent medium, heat inactivated fetal bovine serum
(FBS), geneticin, hygromycin, penicillin, streptomycin,
trypsin-ethylenediaminetetraacetic acid (EDTA), Dul-
becco’s phosphate-buffered saline solution, Hank’s bal-
anced salt solution without phenol red (HBSS w/o phenol
red), HEPES, and Lipofectamine2000TM were all purchased
from Invitrogen (Paisley, UK). Smooth muscle cell
growth medium and supplements were purchased from
Promocell (Heidelberg, Germany). AlphaScreen cAMP
detection kit (containing streptavidin-coated donor beads,
anti-cAMP acceptor beads, biotinylated cAMP, and cAMP
standard) 96-well ViewplatesTM and white 384-well Cultur-
Plates were purchased from Perkin Elmer Life Sciences
(Boston, MA). Bovine serum albumin (BSA), Tween-20,
isoprenaline, rolipram, were purchased from Sigma
Aldrich (Poole, UK).
Cell culture
Human bronchial smooth muscle cells (hBSMc) were
routinely cultured at 37°C, 5% CO2 in smooth muscle
cell growth medium, supplemented with FBS (5% v/v),
epidermal growth factor (recombinant human –
0.5 ng mL1), basic fibroblast growth factor (recombinant
human – 2 ng mL1), and insulin (recombinant human –
5 lg mL1).
U2OS cells were maintained in McCoys 5A medium
supplemented with FBS (10% v/v) at 37°C, 5% CO2. A
stable cell line expressing a b2 adrenoceptor eGFP con-
struct was generated using Lipofectamine2000TM transfec-
tion according to manufacturer’s instructions, followed by
clonal selection (from here on referred to as U2OS-
b2eGFP). Expression was maintained using antibiotic
selection (500 lg mL1 geneticin).
CHO-b2:arrestin cells (DiscoveRx) were maintained in
Ham’s F12 nutrient mix supplemented with FBS (10% v/
v), penicillin (100 IU mL1), streptomycin
(100 lg mL1), hygromycin (200 lg mL1), and geneti-
cin (600 lg mL1) at 37°C, 5% CO2.
For experiments, all of the cells detailed above were
harvested using trypsin/EDTA and seeded on to multiwell
plates in their subculture medium.
Measurement of cAMP in hBSMc cells using
AlphaScreen technology EC50
determinations
Cells were seeded into 96-well ViewPlatesTM at 20,000 cells
per well in culture medium and grown at 37°C, 5% CO2
for 24 h. Spent medium was removed and cells washed
19 with assay buffer (HBSS w/o phenol red, 5 mmol/L
HEPES, 5 lmol/L Rolipram and 0.1% [v/v] BSA). A
range of concentrations of agonist were added to the wells
and incubated with the cells for 2 h at 37°C. This was fol-
lowed by the addition of lysis buffer (dH2O, 0.3% [v/v]
Tween-20) containing 20 units mL1 streptavidin-coated
donor beads and biotinylated cAMP (preincubated for
30 min), and 20 units mL1 anti-cAMP acceptor beads
added to the buffer just before addition to the assay plate.
The plate was then incubated in the dark, at room tem-
perature for 60 min, and read on the Envision plate
reader (Perkin Elmer). A cAMP standard curve was con-
structed in each experiment – the concentration range
covered was 10,000–0.001 nmol/L. The cAMP standard
was diluted in assay buffer and lysis buffer containing the
bead mix was added to the standard curve at the same
time it was added to the wells of the assay.
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Experiments to investigate loss of receptor
function following prolonged incubation
with agonist
As described previously, cells were seeded into 96-well
ViewPlatesTM at 20,000 cells per well in culture medium
and grown at 37°C, 5% CO2 for 24 h. Spent medium was
removed from each well and replaced with either fresh
medium or a range of concentrations of b2 adrenoceptor
agonists which had been serially diluted in cell culture
medium containing 0.01% (w/v) ascorbic acid to prevent
compound oxidation. The cells were incubated with ago-
nist at 37°C, 5% CO2 for between 1 and 24 h, before the
medium was removed and the cells were washed 59 with
assay buffer (HBSS w/o phenol red, 5 mmol/L HEPES,
5 lmol/L rolipram, and 0.1% [v/v] BSA) to remove any
exported cAMP and BackSeal was applied to the plate. A
range of agonist concentrations which matched those
used for pretreatment were diluted in assay buffer and
transferred to the cell plate. In effect, if cells had been
pretreated with a range of concentrations of isoprenaline,
then the same concentration range of isoprenaline was
added back to the cells following the wash step. As a con-
trol, cells which had been incubated with media alone
were also exposed to the same concentration range of
agonist. The cells were incubated for 2 h at 37°C, as this
gave a robust signal in this cAMP accumulation assay.
The incubation was terminated by the addition of lysis
buffer (dH2O, 0.3% [v/v] Tween-20) containing
20 units mL1 streptavidin-coated donor beads and bioti-
nylated cAMP (preincubated for 30 min) and
20 units mL1 anti-cAMP acceptor beads, added to the
buffer just before addition to the assay plate. The assay
plate and standard curve plate were incubated in the dark,
for at least 60 min, at room temperature. The plate was
then read on the Envision plate reader (Perkin Elmer).
Internalization assay
U2OS-b2eGFP cells were seeded overnight in black, clear
bottomed 384-well ViewPlates (Greiner, UK) at 3000
cells/well. On the day of the experiment, spent medium
was removed and replaced with 40 lL CO2-independent
medium supplemented with FBS (10% v/v) and Hoechst
nuclei stain (1 lmol/L). Cells were stimulated with 20 lL
of b2 adrenoceptor agonists for between 0 and 2 h, and
imaged using ImageXpress Micro automated imaging sys-
tem on the IX500 (Molecular Devices, Sunnydale, CA).
All experimental manipulations with viable cells were per-
formed at 30°C to minimize assay medium evaporation
during extended time courses. Images were collected
using an 409 objective and a Peltier cooled CCD camera
(1280 9 1024 pixel). Exposure times were 5 msec for
DAPI (nuclear stain) and 200 msec for fluorescein isothi-
ocyanate (b2eGFP). Cellular image analysis was per-
formed using MetaXpress software and Timelapse analysis
journals embedded with the Transfluor application mod-
ule to measure the appearance of vesicles (1.4–2.2 lm)
containing the b2eGFP receptor over time.
Measurement of b-arrestin-2 recruitment
using enzyme fragment complementation
The PathHunterTM b-arrestin-2 assay (DiscoveRx) uses
enzyme fragment complementation between two portions
of b-galactosidase to measure recruitment of b-arrestin-2
to a GPCR after activation. The larger portion (EA tag) is
fused to b-arrestin-2 and the smaller portion (ProLinkTM)
is fused to the C-terminus of the GPCR of choice. Activa-
tion of the receptor causes recruitment of b-arrestin-2 to
the GPCR thus forming a functional b-galactosidase
enzyme whose activity can be measured by the addition
of a chemiluminescent substrate. CHO-b2:arrestin cells
were seeded into opaque 384-well CulturPlates (Perkin-
Elmer, UK) at 3000 cells/well and grown at 37°C, 5%
CO2 for 24 h prior to agonist treatment. On the day of
the assay, medium was removed and replaced with HBSS
containing 0.1% BSA (w/v) and 20 mmol/L HEPES, at
pH 7.4. Cells were stimulated with a range of b2 adreno-
ceptor agonists for between 15 min and 6 h at 37°C, 5%
CO2. Following incubation, 25 lL of proprietary Flash
reagent mixed with lysis buffer was added to each well,
and luminescence was read after 3 min on the Leadseeker
plate reader (GE Healthcare, UK).
Data analysis
The amount of cAMP detected by the AlphaScreen cAMP
kit was quantified using the Envision plate reader (Perkin
Elmer). To account for the interassay variation in levels
of cAMP which were produced, in each experiment, the
data for the cells which had been pretreated with agonist
were expressed as a percentage of its respective control
cells which had not been pretreated with agonist.
Analysis was performed using Prism 4.0 (GraphPad
Software Inc., San Diego, CA). % maximum isoprenaline
response values for each agonist concentration response
curve were analyzed by nonlinear regression, sigmoidal
dose response (variable slope) according to the following
equation:
Y ¼ Bottomþ ðTop BottomÞ
1þ 10^ððLogEC20  XÞ HillslopeÞ
where Y is the % maximum isoprenaline response, Top
denotes maximal asymptotic percentage response, and
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Bottom denotes the minimal asymptotic percentage
response. This generated pEC50 values and % Emax for
each agonist under all conditions. Data are summarized
as mean  SEM from n number of individual experi-
ments.
For internalization time-course experiments, data were
analyzed by nonlinear regression, polynomial: first order
(straight) line according to the following equation:
Y ¼ Interceptþ Slope  X
where Y is the % maximum isoprenaline response. The
rate of internalization was calculated using the slope of
the fit between 2 and 15 min postagonist addition.
To calculate the rate of b-arrestin-2 recruitment, data
were analyzed using nonlinear regression, one phase expo-
nential association according to the following equation:
Y ¼ Ymax  ð1 expðK  XÞÞ
where Y is the % maximum isoprenaline response, start-
ing at zero and ascending to Ymax with the rate constant
K. The rate half-time is calculated as 0.69/K.
To determine if rates were significantly different, a
one-way analysis of variance (ANOVA) was performed,
followed by Tukey multiple comparison test.
Results
Investigating cAMP signaling in hBSMc
following chronic agonist treatment
By monitoring b2 adrenoceptor agonist-induced cAMP
signaling in the hBSMc, we demonstrated that the agon-
ists tested showed a range of potencies and intrinsic effi-
cacies in these cells (Fig. 1, Table 1).
When hBSMc were pretreated with a range of concentra-
tions of each agonist for 3 h or more, washed to remove any
exported cAMP, and then exposed to the same concentra-
tion of agonist for a further 2 h, each of the agonists tested
showed a loss in maximal amount of cAMP production
compared to control cells (Fig. 2). In addition, the degree of
reduction in cAMP signaling correlated with the length of
agonist pretreatment, with the greatest reduction observed
after 24 h of agonist exposure. After this duration of agonist
exposure the levels of cAMP produced by readdition of each
agonist had been reduced by similar amounts, when com-
pared to their own control responses (75.9% for isoprena-
line; 76.2% for formoterol; 73.3% for indacaterol; 80.4% for
salmeterol). Figure 3A shows that, additionally, the rate of
loss of cAMP signaling, which plateaus between 6 and 24 h,
is almost identical for each of the agonists tested. The data
in Figure 2, 3A were calculated by comparing each agonist
to itself in control conditions. The data in Figure 3B show
the loss of cAMP signaling with time, but it is plotted as a
percentage of the maximal control isoprenaline response.
This highlights the differences in the initial levels of cAMP
which are produced between the high–moderate and low-
efficacy agonists and also shows that in the case of salmeter-
ol the levels of cAMP after 24 h pretreatment are only
approximately 5% of the maximal control isoprenaline
response. In addition, it also shows that even after full
desensitization (post 24 h), isoprenaline, formoterol, and
indacaterol still generate approximately the same amount
of cAMP in these cells as salmeterol does predesensitization
(t = 0). Finally, the loss of cAMP signaling at equi-effective
concentrations was studied. In order to look at this the
concentration of agonist which produced 20% of the
control isoprenaline response was determined from Fig-
ure 1 (4.5 nmol/L isoprenaline, 4 nmol/L indacaterol,
11.2 nmol/L salmeterol, and 1.2 nmol/L formoterol). This
concentration of agonist was then used to calculate the %
cAMP signal remaining at each time point (Fig. 3C). The
data show that at equi-effective concentrations all of the
agonists show a similar rate of loss of cAMP signaling. The
% cAMP response remaining after 3 h treatment with each
agonist was compared by one-way ANOVA, and shown to
be significantly different between isoprenaline and salme-
terol (P < 0.001), indacaterol and salmeterol (P < 0.05),
and isoprenaline and formoterol (P < 0.05), suggesting
that salmeterol is apparently faster to desensitize than the
fuller agonists.
Monitoring b2 adrenoceptor internalization
over time
After demonstrating that all the ligands we tested resulted
in functional desensitization of the cAMP response in
Figure 1. b2 adrenoceptor-mediated cAMP accumulation in hBSMc.
Concentration effect curves for cAMP generation were determined in
hBSMc following exposure to b2 adrenoceptor agonists for 2 h. For
each individual experiment, data have been normalized to the
maximum amount of cAMP produced after addition of 10 lmol/L
isoprenaline, and are expressed as means  SEM for three
independent experiments.
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hBSMc, we then aimed to determine if these agonists were
capable of causing receptor internalization. Unfortunately
there are, as yet, no reagents suitable for monitoring endog-
enous b2 adrenoceptors using immunocytochemical (ICC)
or immunofluorescent (IFC) approaches. In addition, the
level of receptor expression in hBSMc was insufficient to
obtain specific binding of fluorescently labeled agonists or
antagonists (data not shown). The only radioligand cur-
rently available with sufficiently high specific activity to do
detect the low levels of receptors expressed in primary cells
is [I125]-cynopindolol, which is a highly lipophilic ligand
that demonstrates significant cell penetration and mem-
brane partitioning. For this reason we were unable to use
radioligand binding to measure receptor internalization
due to significant contamination from internalized
receptors.
In order to monitor receptor internalization, we there-
fore used U2OS cells expressing endogenous b-arrestin-2,
which were stably transfected with an eGFP-tagged b2
adrenoceptor. This assay was used to measure the kinetics
and extent of receptor internalization in response to
agonist treatment. To this end, a time course of b2
(A) (B)
(C) (D)
Figure 2. Loss of cAMP signaling in hBSMc following chronic b2 adrenoceptor agonist exposure. hBSMc were pretreated with indicated
concentrations of isoprenaline (A), salmeterol (B), indacaterol (C), or formoterol (D) for between 0 and 24 h, washed, and then exposed the same
concentration of agonist for a further 2 h. For each individual experiment, data have been normalized to the maximum amount of cAMP
produced by agonist in cells which have not been previously exposed to agonist. Data shown are expressed as means  SEM for three
independent experiments.
Table 1. Potency and efficacy of b2 adrenoceptor agonists in cAMP accumulation, b-arrestin-2 recruitment, and internalization assays.
cAMP Internalization b-arrestin-2 recruitment
pEC50 % max response pEC50 % max response pEC50 % max response
Isoprenaline 7.8  0.11 100 8.2  0.2 100 7.8  0.11 100
Formoterol 8.8  0.19 98.5  1.8 9.1  0.2 96.6  5.8 8.8  0.12 108  4.8
Indacaterol 8.2  0.09 87.2  3.6 8.6  0.1 95.1  3.6 7.8  0.10 98.3  6.0
Salbutamol 6.7  0.03 48.2  1.4 7.0  0.1 68.8  3.9 6.9  0.07 56.0  3.9
Salmeterol 9.0  0.26 34.2  5.8 8.9  0.3 43.7  4.1 8.4  0.08 27.1  2.5
Data are expressed as means  SEM for three independent experiments (3–5 for internalization). Potency and efficacy of b2 adrenoceptor agon-
ists in cAMP accumulation using hBSMc (AlphaScreen), b-arrestin-2 recruitment in PathHunter CHO-b2:arrestin cells, and internalization in U2OS-
b2GFP cells. pEC50 values were calculated after a 2 h (cAMP and internalization) or 4 h stimulation (b-arrestin-2 recruitment) with b2 adrenocep-
tor agonists. Emax was calculated as a percentage of maximal isoprenaline response.
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adrenoceptor internalization was constructed for each
agonist over a range of concentrations (10,000–0.1 nmol/
L).
For all of the agonists tested internalization of the b2
adrenoceptor was observed, as shown in Figure 4. In
addition, this was shown to be concentration-dependent
(Fig. 5A) and pEC50 values could be determined, as
shown in Table 1. The extent to which receptors internal-
ized varied between agonists, with isoprenaline causing
the greatest amount of internalization, followed by for-
moterol, indacaterol, and salbutamol with salmeterol
causing the least amount of internalization. From these
data, EC80 concentrations were derived and the rate of
internalization was compared for each agonist (Fig. 5B,
Table 2). The rates were shown to be significantly differ-
ent when compared by one-way ANOVA (P < 0.0001).
Isoprenaline had the fastest onset of receptor internaliza-
tion, followed by formoterol, indacaterol, salbutamol, and
salmeterol.
b-arrestin-2 recruitment
Using the highly sensitive U2OS-b2eGFP internalization
assay, we were able to demonstrate that all agonists tested
were capable of causing b2 adrenoceptor internalization.
We then aimed to determine if all agonists were also
capable of causing b-arrestin-2 recruitment. The Path-
HunterTM b-arrestin-2 assay was used to measure b-arres-
tin-2 recruitment to the b2 adrenoceptor as a
consequence of agonist stimulation of the receptor. Full
concentration response curves were performed for each
agonist for between 15 min and 6 h (Fig. 6A). The
potency was lower at 15 min than 2 h for all of the agon-
ists tested, although the time taken to reach full potency
varied for each agonist. Despite this, rank order of
potency did not change with increasing stimulation time,
the mean pEC50 values for each agonist following a 2 h
stimulation are shown in Table 1. A time course of b-arr-
estin-2 recruitment was then constructed for EC80 con-
centrations of each agonist (Fig. 6B).
The requirement for complementation to occur
between the two portions of b-galactosidase following b-
arrestin-2 recruitment and the rate of the subsequent
enzyme reaction that produces the luminescent signal
appears to cause a lag in the kinetics observed with this
assay. It has been demonstrated previously using FRET
measurements that the kinetics of b-arrestin-2 associa-
tions with the b2 adrenoceptor occur with a t1/2 of
19.6 sec (Krasel et al. 2004), although these experiments
were performed in the presence of cotransfected GRKs
which may also contribute to the faster rates observed. In
contrast, measurement of the same associations with the
b-galactosidase fragmentation complementation method
(A)
(B)
(C)
Figure 3. Rate of loss of cAMP signaling in hBSMc following chronic
b2 adrenoceptor agonist exposure. (A) Rate of loss of cAMP signaling in
hBSMc following pretreatment with b2 adrenoceptor agonists. Data
shown are expressed as means  SEM for three independent
experiments. (B) Relative levels of cAMP (% response compared to
isoprenaline) produced in human bronchial smooth muscle cells
following treatment with different b2 adrenoceptor agonists over a
24 h time period. Data shown are single determinations from a single
experiment, which is representative of three independent experiments.
(C) Rate of loss of cAMP signaling in human bronchial smooth muscle
cells following pretreatment with a concentration of b2 adrenoceptor
agonist which produces an amount of cAMP equivalent to 20% of the
isoprenaline response. Specifically, these concentrations were 4.5 nmol/
L isoprenaline, 4 nmol/L indacaterol, 11.2 nmol/L salmeterol, and
1.2 nmol/L formoterol. These concentrations were taken from the data
generated in Figure 2 and normalized to 20% isoprenaline. Data shown
are expressed as means  SEM for three independent experiments.
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used here can take 1–4 h to reach maximal activation
(Fig. 6B). This is similar to previous work using comple-
mentation assays, where a treatment time of 1 h was
required to produce a maximal response (Carter and Hill
2005). This implies that while the assay is useful in mea-
suring comparative rates, allowing us to rank agonists
against each other, it does not represent the true rate of
b-arrestin-2 recruitment that would be observed in a
physiological system.
Despite this limitation, we were able to measure differ-
ences in the onset of action for each agonist. Isoprenaline
had the fastest onset of b-arrestin-2 recruitment followed
by formoterol, indacaterol, salbutamol, and salmeterol, K
Figure 4. b2 adrenoceptor agonist-mediated receptor internalization. Agonist-dependent formation of b2eGFP containing vesicles following
stimulation of U2OS-b2eGFP cells with an EC50 concentration of agonist (derived from Fig. 5) for 60 or 90 min in the case of salmeterol. Images
were performed using ImageXpress Micro automated imaging system on the IX500 (Molecular Devices). Images were collected using a 409
objective and a Peltier cooled CCD camera. b2eGFP receptors were detected using fluorescein isothiocyanate filter and a 200 msec exposure
time.
(A)
(B)
Figure 5. Concentration- and time dependency of receptor-mediated
b2-adrenoceptor internalization in U2OS-b2GFP cells. (A)
Concentration-dependent increases in b2 adrenoceptor internalization
were assessed between 0 and 2 h stimulation with the indicated
concentrations of b2 adrenoceptor agonists. (B) Time-dependent
increases in b2 adrenoceptor internalization for between 0 and 2 h
after stimulation of cells with approximately EC80 concentrations of
agonist (as determined from A). Slope factors (K) determined for
initial rate of b2 adrenoceptor internalization (between 0 and 45 min)
from polynomial first order (straight) line fit. For each individual
experiment, data have been normalized to the maximum amount of
b2 adrenoceptor internalization detected after addition of 10 lmol/L
isoprenaline, and are expressed as mean  SEM for 3–5 independent
experiments.
Table 2. Rate of b2 adrenoceptor-mediated b-arrestin-2 recruitment
and internalization.
K value (% max isoprenaline response per minute)
Internalization b-arrestin-2 recruitment
Isoprenaline 2.58  0.15 0.032  0.002
Formoterol 1.50  0.17 0.024  0.001
Indacaterol 1.22  0.10 0.016  0.001
Salbutamol 0.82  0.15 0.013  0.001
Salmeterol 0.55  0.16 0.008  0.002
Data are expressed as means  SEM for three independent experi-
ments (3–5 for internalization). Rate of receptor-mediated internaliza-
tion in U2OS-b2GFP cells and b-arrestin-2 recruitment in PathHunter
CHO-b2:arrestin cells, generated using an EC80 concentration of ago-
nist. Slope factors (K) were determined for rate of b-arrestin-2 recruit-
ment by fitting data to a monoexponetial curve, or initial rate of b2
adrenoceptor internalization (between 0 and 45 min) from polynomial
first order (straight) line fit.
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values are shown in Table 2. Rates of b-arrestin-2 recruit-
ment determined from EC80 concentrations of agonist
were compared by one-way ANOVA, and shown to be
significantly different with P < 0.0001. In addition, when
comparing individual agonists, the high-efficacy ligands
isoprenaline and formoterol were shown to have signifi-
cantly faster rates of b-arrestin-2 recruitment than the
lower efficacy ligands (all with P < 0.05).
Discussion
b2 adrenoceptor agonists have been used extensively in
the treatment of pulmonary disorders such as asthma and
COPD. As these disorders are chronic in nature they
require long-term treatment with the b2 adrenoceptor ag-
onists which may lead to a loss of responsiveness through
tachyphylaxis. There have been a number of clinical stud-
ies that have investigated the long-term b2 adrenoceptor
therapy (20–24 weeks), but very few so far that have
investigated tachyphylaxis for periods of greater than
6 months. Those that have been completed so far have
yielded conflicting results with some studies indicating
tachyphylaxis does occur, whereas others suggest little or
no loss of efficacy upon long-term treatment (Steffensen
et al. 1995; FitzGerald et al. 1999; Donohue et al. 2002,
2003; Hanania et al. 2005). Here we have attempted to
model some of the processes involved in tachyphylaxis in
order to understand these discrepancies more fully. To
this end, we have investigated a number of b2 adrenocep-
tor agonists for their ability to cause in vitro functional
desensitization of cAMP responses in hBSMc after repeat
exposure to the same agonist. In addition, we have inves-
tigated their ability to cause receptor internalization and
the recruitment of b-arrestin-2.
Early studies examining receptor desensitization of the
b2 adrenoceptor showed a clear relationship between ago-
nist efficacy and desensitization, with partial b2 agonists
causing less phosphorylation and internalization than full
agonists (January et al. 1997; Clark et al. 1999). However,
these early experiments conducted with the b2 agonists
were designed so that receptor occupancy was matched
for each agonist, regardless of efficacy. This effectively
negated any influence of receptor reserve and meant that
agonists were tested at concentrations that gave markedly
different functional effects. Importantly, clinical doses are
chosen based on functional effect not receptor occupancy,
so these early studies are not useful for understanding the
tendency of particular agonists to induce tachyphylaxis in
the clinic. One way to compensate for this is to compare
the functional desensitization elicited by agonists at con-
centrations which generate the same functional response,
termed an equi-effective concentration. To date, only
D€uringer et al. (2009) and more recently Cooper et al.
(2011) have used equi-effective concentrations of agonists
while investigating functional desensitization at the b2
adrenoceptor. In both of these studies, chronic (12–24 h)
stimulation of small airways or isolated human airway
smooth muscle cells resulted in similar loss of responsive-
ness to a subsequent challenge by a high-efficacy agonist
(isoprenaline or formoterol). However, use of a full ago-
nist after chronic challenge may underestimate the
amount of functional desensitization that would be
observed to a partial agonist after chronic treatment with
the same partial agonist. In contrast, the use of a partial
agonist to challenge cells after chronic treatment with a
full agonist may result in greater levels of functional
desensitization. As discussed in Charlton (2009), partial
agonists are required to activate a higher number of
receptors to produce the same response as a full agonist
and so are more susceptible to loss of functional receptors
than the full agonists. In the clinic, patients are on con-
tinuous treatment with the same LABA to maintain target
coverage. In an attempt to more accurately reflect these
(A)
(B)
Figure 6. Concentration- and time dependency of receptor-mediated
b-arrestin-2 recruitment in PathHunterTM CHO-b2:arrestin cells. (A)
Concentration-dependent increases in b-arrestin recruitment were
assessed between 0 and 4 h stimulation with the indicated
concentrations of b2 adrenoceptor agonists. (B) Time-dependent
increases in b-arrestin-2 recruitment for between 0 and 4 h after
stimulation of cells with approximately EC80 concentrations of agonist
(as determined from part A). Data were fit by nonlinear regression to
a one phase exponential association to determine half-life of b-
arrestin-2 recruitment. For each individual experiment, data have been
normalized to the b-arrestin-2 recruitment detected after addition of
10 lmol/L isoprenaline for 4 h, and are expressed as mean  SEM
for three independent experiments.
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conditions in our in vitro studies, we have used the same
agonist for the subsequent rechallenge after prolonged
agonist treatment. In addition, we chose to run full con-
centration response curves for each agonist.
This protocol revealed that all of the agonists tested
produced functional desensitization to the cAMP response
in hBSMc to the same extent. In addition, the rate of loss
of cAMP signaling was shown to be similar for all of the
agonists tested when considering either the maximum loss
in signaling or equi-effective concentrations. Conse-
quently, from this study our data indicate that neither the
extent nor rate of functional desensitization are correlated
with agonist efficacy. The time course we have observed
in our functional desensitization studies is somewhat
slower than might be expected if these responses were
solely due to receptor phosphorylation, arrestin binding
to the receptor or receptor internalization. We started to
see functional desensitization after 3 h of treatment (1 h
for salmeterol) that successively increased over time. This
suggests that functional desensitization is a combination
of many factors and is a much more complex process.
This most likely includes specific receptor modifications
such as phosphorylation, b-arrestin recruitment, and
internalization at the shorter time points, followed by
receptor downregulation at the later time points. In addi-
tion, we now know that processes such as these do not
necessarily lead to complete shutdown of receptor signal-
ing but may activate alternative signaling pathways
(Shenoy and Lefkowitz 2005).
This lack of correlation may be explained by revisiting
the relationship between efficacy and receptor occupancy.
Although lower efficacy agonists cause less receptor modi-
fication such as b-arrestin-2 recruitment and internaliza-
tion, they require a greater number of receptors to be
occupied to generate a subsequent response and will
therefore be sensitive to even a small reduction in recep-
tor number. In contrast, although higher efficacy agonists
cause more receptor modification they require fewer
receptors to be activated to give a subsequent response,
so will be more resistant to loss of receptors. Interestingly,
as has been shown in this study, in both situations you
would expect to observe some functional desensitization,
this is discussed in more detail by Charlton (2009). In
these studies, we observed rapid functional desensitization
to each agonist within the first 6 h of treatment, which
plateaued between 6 and 24 h.
It is also worth considering the relative levels of cAMP
that are produced for each of the agonists following pro-
longed agonist exposure and functional desensitization,
highlighted by the data shown in Figure 3B. Initially the
amount of cAMP produced by salmeterol was just over
20% of that produced by isoprenaline. After 24 h exposure,
the response was reduced by about 75–80% for all of the
agonists tested. This means that salmeterol only generates
4% of the original isoprenaline response, compared to 20%
for isoprenaline and formoterol and approximately 15%
for indacaterol. So, despite the fact that each agonist shows
the same percentage of functional desensitization of the
cAMP response, isoprenaline, formoterol, and indacaterol
generate a similar absolute amount of cAMP after chronic
exposure as salmeterol does before desensitization. This
suggests that very low-efficacy agonists may be more sensi-
tive to loss of functional response upon repeated exposure
and might not maintain a sufficient cAMP signal to sustain
full 24 h bronchodilation.
We have reason to speculate that the levels of cAMP
required to cause bronchodilation may be quite low given
that in the presence of substantial functional desensitiza-
tion in vitro, in the clinic 24 h bronchodilation is
observed with LABAs. Additionally, in a number of stud-
ies (Steffensen et al. 1995; FitzGerald et al. 1999; Don-
ohue et al. 2002, 2003; Hanania et al. 2005) loss of
efficacy is not observed following long-term treatment
with b2 adrenoceptor agonists. In this study we have mea-
sured global cAMP production which could be a potential
limitation as contraction/relaxation could be driven by
compartmentalization of high concentrations of cAMP into
areas localized with contractile machinery. It has also been
demonstrated that there is a higher receptor reserve present
in airway smooth muscle cells compared to other cells, such
as mast cells, that express the b2 adrenoceptor agonists.
This may help to explain why the airway is more resistant
to substantial receptor internalization and b-arrestin-2
recruitment, to maintain bronchodilation when other cell
types rapidly desensitize immunomodulatory effects such
as histamine release (Chong and Peachell 1999).
One of the major steps involved in clathrin-dependent
GPCR internalization is the recruitment of b-arrestin-2
following agonist occupation of the receptor and GRK-
site phosphorylation ultimately leading to receptor inter-
nalization. We have investigated this pathway at two
points, to determine whether the b2 adrenoceptor agonists
are capable of activating these processes. First, we have
used an eGFP-tagged b2 adrenoceptor and endogenous b-
arrestin-2 to monitor real-time changes in surface recep-
tor expression using fluorescence imaging, and second the
PathHunterTM assay to measure recruitment of b-arrestin-
2 to activated receptor using a complementation assay.
To monitor receptor internalization, we have used a
system that utilizes endogenous b-arrestin but a recombi-
nant eGFP-tagged receptor, which allowed us to develop
a highly sensitive assay. In low expression systems,
although receptors may be causing internalization, if there
are not enough receptors in the same locale no fluores-
cent signal will be detected. This may lead to incorrect
assumptions regarding partial agonists, and may explain
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why some studies demonstrate internalization to salmeter-
ol (January et al. 1998; Kallal et al. 1998; Cooper et al.
2011), and others do not, despite showing GRK-site phos-
phorylation (Moore et al. 2007). We have shown that all
of the agonists tested were capable of inducing receptor
internalization with different intrinsic efficacies. In addi-
tion, we observed a relationship between the degree and
the rate at which internalization occurred, such that
agonists that were more fully efficacious in this assay had
faster internalization rates than the agonists which were
partial. This is in contrast to work by Moore et al.
(2007), who concluded that the partial agonist salmeterol
was incapable of causing significant endocytosis of the b2
adrenoceptor. The initial endocytosis experiments in their
study were performed after 15 min, in which time we do
not observe endocytosis in response to salmeterol either.
Using quantitative Enzyme-linked immunosorbent assay
(ELISA), they then demonstrated that over a 60 min
incubation, salmeterol was a weak partial agonist, causing
only 5% internalization compared to 60% for formoterol.
However, when overexpressing eGFP-labeled b-arrestin-2,
salmeterol was capable of causing significant receptor
internalization after 15 min treatment (Moore et al.
2007). In agreement with our results, Cooper et al. (2011)
demonstrated using adenoviral expression of Ad5-CMV-
human b2 adrenoceptor-YFP in human lung slices (airway
epithelial cells) that salmeterol is capable of internalizing
the b2 adrenoceptor, but at a much reduced level com-
pared to formoterol.
Using the complementation assay, we also demon-
strated that all ligands were capable of recruiting b-arres-
tin-2, and that similar to the internalization assay the
agonists did so with a range of intrinsic efficacies and
rates. Again, this is in contrast to the work by Moore and
colleagues, who did not demonstrate any recruitment of
b-arrestin-2 to the b2 adrenoceptor after salmeterol chal-
lenge. A possible explanation for these different observa-
tions is that 2 min was not sufficient time to observe
arrestin recruitment in response to salmeterol. Here we
have demonstrated that the time-course of b-arrestin-2
recruitment is dependent on agonist intrinsic efficacy as
measured in the same assay, so it is likely that the 2 min
treatment used by Moore et al. (2007) was insufficient for
salmeterol, despite being appropriate for higher efficacy
ligands. An alternative explanation could be that the
highly sensitive assay systems we have utilized in these
studies are more adept at measuring the small responses
to partial agonists such as salmeterol and salbutamol.
In summary, in agreement with many other studies
performed to date, we find that high-efficacy agonists
cause more b-arrestin-2 recruitment and receptor inter-
nalization. Historically, a direct relationship has been
assumed between the data generated from receptor
modification studies such as these, and functional desen-
sitization. However, in our study where we have investi-
gated cAMP responses in hBMSC we have shown that the
higher efficacy agonists do not produce a higher degree of
functional desensitization. In fact, under conditions that
are more akin to the clinical situation where cells are
chronically stimulated and then rechallenged with the
same agonist, all of the agonists, regardless of their effi-
cacy, produce the same degree of functional desensitiza-
tion. With this in mind, higher efficacy agonists may
provide a more sustained effect as the residual levels of
cAMP produced following chronic agonist treatment may
still be sufficient to maintain a bronchodilatory effect,
even after 24 h. In agreement with these preclinical obser-
vations, no loss of bronchodilatory effect is observed in
COPD patients following prolonged administration of the
high-efficacy agonist indacaterol (Chapman et al. 2011).
Finally, these data may also have clinical relevance outside
the field of LABA therapy where GPCR agonists are used
chronically for the treatment of disease.
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